Systemic LymphoBlastoid Interferon Therapy In C/P Multiple Sclerosis

I. Clinical and MRI evaluation

Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, Koopmans RA, Petkau AJ, Berkowitz J, Paty DW
Neurology 1990 Mar;40(3 Pt 1):479-86
Univ of British Columbia, Division of Neurology, Vancouver, Canada

UI# 90191149

A randomized, double-blind, placebo controlled, noncrossover trial determined the efficacy of LymphoBlastoid Interferon (IFN) in Chronic Progressive Multiple Sclerosis (CP MS).

Fifty patients received 5 X 10(6) IU IFN subcutaneously daily for 6 months while 50 received placebo. After 2 years, there were no significant differences between the 2 groups based on clinical evaluations and quantitative MRI analysis of the Brain, although a trend was observed in the IFN group.

Clinically, the IFN group was worse at 1 and 3 months and improved at 6 to 18 months, when compared with the placebo group. Results of MRI evaluations of the Brain at 6 months support this trend.

This trend likely resulted from a subpopulation of 10 IFN-treated patients, characterized by a higher women:men ratio and a lower EDSS score at entry into the trial. We cannot recommend LymphoBlastoid IFN as treatment for CP MS at this time.

Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology

MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index

ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses

Copyright 1997 - 2010:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.